可利霉素治疗广泛耐药鲍曼不动杆菌重症肺炎1例
Carrimycin in the Treatment of Severe Pneumonia Caused by Extensively Drug-Resistant Acinetobacter baumannii: A Case Report
DOI: 10.12677/acm.2025.1551483, PDF,   
作者: 崔 媛, 尹聪聪:长治医学院第一临床医学院,山西 长治;秦睿君, 乔可宏:太原市中心医院呼吸与危重症医学科,山西 太原
关键词: 可利霉素广泛耐药鲍曼不动杆菌疗效评价Carrimycin Extensively Drug-Resistant Acinetobacter baumannii (XDRAB) Efficacy Evaluation
摘要: 广泛耐药鲍曼不动杆菌(Extensively Drug Resistant Acinetobacter baumannii, XDRAB)是指对仅有1~2种可能具有抗菌活性的药物(主要是替加环素和/或多黏菌素)敏感的菌株。它是一种人类机会性致病菌,尤其在长期住院的患者中更为常见。XDRAB的治疗一直是一个难题。本文报告了一例医院获得性XDRAB感染导致的重症肺炎患者的治疗过程。我们先后使用了哌拉西林钠他唑巴坦钠、美罗培南、万古霉素及多粘菌素等多种抗生素,但效果不佳。最终通过联合使用可利霉素治疗,患者病情得到改善并顺利出院。本文通过分析该病例的临床特点及诊治过程,并复习相关文献,旨在提高临床医生对XDRAB的诊治水平,并希望为进一步研究其体内外抗菌作用提供参考。
Abstract: Extensively Drug-Resistant Acinetobacter baumannii (XDRAB) refers to strains that are susceptible to only one or two potentially active antimicrobial agents (primarily tigecycline and/or polymyxins). It is an opportunistic human pathogen, particularly prevalent among long-term hospitalized patients. The treatment of XDRAB has remained a significant challenge. This article reports the treatment process of a patient with severe pneumonia caused by hospital-acquired XDRAB infection. We sequentially administered multiple antibiotics, including piperacillin sodium-tazobactam sodium, meropenem, vancomycin, and polymyxin, but the response was poor. Ultimately, the patient’s condition improved and they were successfully discharged after combination therapy with carrimycin. By analyzing the clinical characteristics, diagnosis, and treatment process of this case and reviewing relevant literature, this study aims to enhance clinicians’ understanding of XDRAB management and provide a reference for further research on its in vitro and in vivo antibacterial effects.
文章引用:崔媛, 尹聪聪, 秦睿君, 乔可宏. 可利霉素治疗广泛耐药鲍曼不动杆菌重症肺炎1例[J]. 临床医学进展, 2025, 15(5): 1206-1211. https://doi.org/10.12677/acm.2025.1551483

参考文献

[1] Harding, C.M., Hennon, S.W. and Feldman, M.F. (2017) Uncovering the Mechanisms of Acinetobacter Baumannii Virulence. Nature Reviews Microbiology, 16, 91-102. [Google Scholar] [CrossRef] [PubMed]
[2] Mulani, M.S., Kamble, E.E., Kumkar, S.N., Tawre, M.S. and Pardesi, K.R. (2019) Emerging Strategies to Combat ESKAPE Pathogens in the Era of Antimicrobial Resistance: A Review. Frontiers in Microbiology, 10, Article 539. [Google Scholar] [CrossRef] [PubMed]
[3] Van Looveren, M. and Goossens, H. (2004) Antimicrobial Resistance of Acinetobacter Spp. in Europe. Clinical Microbiology and Infection, 10, 684-704. [Google Scholar] [CrossRef] [PubMed]
[4] Munoz-Price, L.S. and Weinstein, R.A. (2008) Acinetobacter Infection. New England Journal of Medicine, 358, 1271-1281. [Google Scholar] [CrossRef] [PubMed]
[5] Falagas, M.E., Bliziotis, I.A. and Siempos, I.I. (2006) Attributable Mortality of Acinetobacter Baumannii Infections in Critically Ill Patients: A Systematic Review of Matched Cohort and Case-Control Studies. Critical Care, 10, R48. [Google Scholar] [CrossRef] [PubMed]
[6] Wu, X., Chavez, J.D., Schweppe, D.K., Zheng, C., Weisbrod, C.R., Eng, J.K., et al. (2016) In Vivo Protein Interaction Network Analysis Reveals Porin-Localized Antibiotic Inactivation in Acinetobacter Baumannii Strain Ab5075. Nature Communications, 7, Article No. 13414. [Google Scholar] [CrossRef] [PubMed]
[7] Vila, J., Martí, S. and Sánchez-Céspedes, J. (2007) Porins, Efflux Pumps and Multidrug Resistance in Acinetobacter Baumannii. Journal of Antimicrobial Chemotherapy, 59, 1210-1215. [Google Scholar] [CrossRef] [PubMed]
[8] Muhammad, M.H., Idris, A.L., Fan, X., Guo, Y., Yu, Y., Jin, X., et al. (2020) Beyond Risk: Bacterial Biofilms and Their Regulating Approaches. Frontiers in Microbiology, 11, Article 928. [Google Scholar] [CrossRef] [PubMed]
[9] Cepas, V., López, Y., Muñoz, E., Rolo, D., Ardanuy, C., Martí, S., et al. (2019) Relationship between Biofilm Formation and Antimicrobial Resistance in Gram-Negative Bacteria. Microbial Drug Resistance, 25, 72-79. [Google Scholar] [CrossRef] [PubMed]
[10] Dehbanipour, R. and Ghalavand, Z. (2022) Acinetobacter baumannii: Pathogenesis, Virulence Factors, Novel Therapeutic Options and Mechanisms of Resistance to Antimicrobial Agents with Emphasis on Tigecycline. Journal of Clinical Pharmacy and Therapeutics, 47, 1875-1884. [Google Scholar] [CrossRef] [PubMed]
[11] 黄晨, 肖永红. 多粘菌素临床应用与困局[J]. 医药导报, 2020, 39(1): 10-16.
[12] Hao, T. and He, W. (2021) Advances in Metabolic Engineering of Macrolide Antibiotics. Chinese Journal of Biotechnology, 37, 1737-1747.
[13] Vázquez-Laslop, N. and Mankin, A.S. (2018) How Macrolide Antibiotics Work. Trends in Biochemical Sciences, 43, 668-684. [Google Scholar] [CrossRef] [PubMed]
[14] Li, X., Luo, Y., Wang, Y., Yang, Z., Shang, Y. and Guan, Q. (2023) Anti-Inflammatory Effect and Antihepatoma Mechanism of Carrimycin. World Journal of Gastroenterology, 29, 2134-2152. [Google Scholar] [CrossRef] [PubMed]